Miraculins Announces Private Placement Offering
WINNIPEG, MANITOBA -- (Marketwire) -- 03/25/13 -- Miraculins Inc.
(TSX VENTURE:MOM), a medical diagnostic company focused on acquiring,
developing and commercializing diagnostic tests and risk assessment
technologies for unmet clinical needs, today announces a non-brokered
private placement offering (the "Offering") of up to 11,111,111 units
("Units") at a price of $0.09 per Unit for gross proceeds of up to
$1,000,000. Each Unit will be comprised of one common share of the
Company (a "Share") and one half of one Share purchase warrant. Each
whole warrant (a "Warrant") will entitle the holder to purchase one
Share at a price of $0.11 per Share for a period of 12 months from
the date the Warrant is issued.
Certain persons may assist the Company by introducing potential
subscribers for the Offering and, subject to compliance with
applicable legislation, will be entitled to receive a finder's fee,
payable in cash and share purchase warrants, as permitted by law.
The net proceeds of the Offering will be used for general corporate
purposes including sales and marketing costs related to the Company's
PreVu(R) Skin Cholesterol Test.
The Offering is subject to receipt of all necessary approvals,
including the approval of the TSX Venture Exchange.
About Miraculins Inc.
Miraculins is a medical diagnostic company focused on acquiring,
developing and commercializing non-invasive tests for unmet clinical
needs. A significant number of promising diagnostic opportunities
remain un-commercialized because of the sizable gap between the
discovery stage, when research institutions are typically involved,
and the commercialization stage, when the larger commercial
enterprises become interested. Miraculins has direct experience in
bridging this gap. The Company's PreVu(R) technology is a
revolutionary new coronary artery disease risk assessment technology
that measures cholesterol levels in a patient's skin non-invasively,
painlessly and without the need for fasting. Miraculins is also
advancing a suite of biomarkers to aid in the early detection of the
devastating disease of pregnancy known as preeclampsia. The lead
marker in the Company's preeclampsia program is partnered with Alere
Inc., one of the world's largest diagnostic companies. For more
information visit www.miraculins.com.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute
forward-looking information within the meaning of applicable Canadian
provincial securities legislation (collectively, "forward-looking
statements"). These forward-looking statements relate to, among other
things, our objectives, goals, targets, strategies, intentions,
plans, beliefs, estimates and outlook, including, without limitation,
our anticipated future operating results, and can, in some cases, be
identified by the use of words such as "believe," "anticipate,"
"expect," "intend," "plan," "will," "may" and other similar
expressions. In addition, any statements that refer to expectations,
projections or other characterizations of future events or
circumstances are forward-looking statements.
These statements reflect management's current beliefs and are based
on information currently available to management. Certain material
factors or assumptions are applied in making forward-looking
statements, and actual results may differ materially from those
expressed or implied in such statements. Important factors that could
cause actual results to differ materially from these expectations
include, among other things: Miraculins' early stage of development,
lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development,
rapid technological change, uncertainties related to forecasts,
competition, potential product liability, additional financing
requirements and access to capital, unproven markets, supply of raw
materials, income tax matters, management of growth, partnerships for
development and commercialization of technology, effects of insurers'
willingness to pay for products, system failures, dependence on key
personnel, foreign currency risk, risks related to regulatory matters
and risks related to intellectual property and other risks detailed
from time to time in Miraculins' filings with Canadian securities
regulatory authorities, as well as Miraculins' ability to anticipate
and manage the risks associated with the foregoing. Additional
information about these factors and about the material factors or
assumptions underlying such forward-looking statements may be found
in the body of this news release. Miraculins cautions that the
foregoing list of important factors that may affect future results is
not exhaustive. When relying on Miraculins' forward-looking
statements to make decisions with respect to Miraculins investors and
others should carefully consider the foregoing factors and other
uncertainties and potential events.
These risks and uncertainties should be considered carefully and
prospective investors should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in this press release are based upon what management
believes to be reasonable assumptions, Miraculins cannot provide
assurance that actual results will be consistent with these
forward-looking statements. Miraculins undertakes no obligation to
update or revise any forward-looking statement.
PreVu(R) is a registered trademark of Miraculins Inc. All Rights
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
Christopher J. Moreau
President & CEO
Press spacebar to pause and continue. Press esc to stop.